Case Report of Warfarin Induced Hemoperitoneum

Life Sciences-Gynaecology


  • Dr.T.G. Revathy Department of obstetrics and gynaecology, Sree Balaji Medical College and Hospital Chrompet, Chennai 600044
  • Dr C. Minu Priya Department of obstetrics and gynaecology, Sree Balaji Medical College and Hospital Chrompet, Chennai 600044



warfarin, anti-coagulant, secondary hemoperitoneum, Bleeding, PT INR.


Although spontaneous hemoperitoneum is a rare condition, it has the potential to be devastating. A common coumarin anti-coagulant used for therapeutic and preventive anticoagulation is warfarin. Despite being a drug that can save lives, it is linked to severe side effects, mainly bleeding. The aim and objective of the study include the unusual occurrence of Hemoperitoneum that an Anti-Coagulant Drug Warfarin induces. Although reports of spontaneous hemoperitoneum in anticoagulant-using individuals have been published in the literature, diagnostic standards and therapeutic approaches have not yet been firmly established. PT INR should be routinely checked when warfarin is prescribed to prevent any problems. Intraabdominal bleeding resulting from non-traumatic reasons or organ rupture within the abdomen is known as spontaneous hemoperitoneum. The presence of intra-abdominal bleeding from a non-traumatic origin is known as spontaneous hemoperitoneum. Hemoperitoneum from warfarin is a known side effect that can be fatal. It might be challenging to manage unexpected bleeding while keeping the INR under control and preventing thrombosis. If the INR is out of range, there is a higher risk of warfarin-induced bleeding. The spontaneous hemoperitoneum described in this case report was caused by warfarin over-toxicity in a patient with rheumatic heart disease. The indications and symptoms resemble a ruptured corpus luteal cyst or an ectopic pregnancy. Although the patients undergoing Anti-coagulant therapy, especially warfarin, may experience other symptoms like GI bleeding, Nausea, Hematuria and so on.


Schattner A, Kozack N, Friedman J. Idiopathic Spontaneous hemoperitoneum. Arch Intern Med. 2001;161(7):1009-10. doi: 10.1001/archinte.161.7.1009, PMID 11295967.

Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anti-coagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 8th ed. 2008;133(6);Suppl:257S-98S. doi: 10.1378/chest.08-0674, PMID 18574268.

Warfarin sodium. The American Society of Health-System Pharmacists. Archived from the original on 18 September 2017. [retrieved Jan 8 2017].

Garcia D, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. BMJ. 2010;340:c1813. doi: 10.1136/bmj.c1813, PMID 20404060.

Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ; et al. Evidence-based management of anti-coagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2);Suppl: e1525- 845:e152S-84S. doi: 10.1378/chest.11-2295, PMCID 3278055. PMID 22315259.

James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295-307. doi: 10.1111/j.1365-2516.2005.01108.x, PMID 16011580.

Natarajan S, Ponde CK, Rajani RM, Jijina F, Gursahani R, Dhairyawan PP et al.. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. Pharmacol Rep. 2013;65(5):1375-82. doi: 10.1016/s1734-1140(13)71496-8. PMID 24399734.

Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5(3):193-202. doi: 10.1038/sj.tpj.6500308, PMID 15824753.

Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy. 2001;21(2):235-42. doi: 10.1592/phco., PMID 11213860.

Lacy CF, Armstrong LL, Goldman M, Lance LL, editors. Drug information handbook 2001-2002. 9th ed. Cleveland: Lexy-Comp; 2001. p. 1287-91.

Kulkarni V, Bhave A, Munshi RK, Bhalerao S, Bhattad D, Khude S et al. Warfarin therapy–why one dose does not fit all! J Assoc Physicians India. 2013;61(8):571-3. PMID 24818346.

Abbas MA, Collins JM, Olden KW. Spontaneous intramural small-bowel hematoma: imaging findings and outcome. AJR Am J Roentgenol. 2002;179:1389-94;179(6):1389-94. doi: 10.2214/ajr.179.6.1791389, PMID 12438021.

American College of Obstetricians and Gynecologists (ACOG). Thromboembolism in pregnancy. Washington, (DC): American College of Obstetricians and Gynecologists (American College of Obstetricians and Gynecologists); 2011 September 12 p. (ACOG practice bulletin; no. 123).

Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anti-coagulant treatment. Chest. 1995;108(4);Suppl:276S-90S. doi: 10.1378/chest.108.4_supplement.276s, PMID 7555182.

Killian ST, Heitzman EJ. Intramural haemorrhage of the small intestine due to anti-coagulants. JAMA. 1967;200(7):591-4. doi: 10.1001/jama.1967.03120200069009, PMID 5297869.

Bangal VB, Shinde KK, Borawake SK. Warfarin toxicity presenting as a ruptured ovarian tumour with hemoperitoneum: a case report. Int J of Biomed & Adv Res. 2012;3(3):209-11. doi: 10.7439/ijbar.v3i3.334.



How to Cite

Revathy, D., & Minu Priya, D. C. . (2023). Case Report of Warfarin Induced Hemoperitoneum: Life Sciences-Gynaecology. International Journal of Life Science and Pharma Research, 13(3), L145-L149.



Case Study